Thermo Fisher Scientific, a global leader in serving science, has unveiled the new Olink Target 48 Neurodegeneration panel — a high-performance targeted proteomics immunoassay panel designed to accelerate breakthroughs in neurodegenerative disease research.
With rising global prevalence of conditions such as Alzheimer’s disease, multiple sclerosis, and Parkinson’s disease, researchers urgently need scalable, reproducible, and disease-relevant protein measurement tools. The new panel addresses this need by enabling simultaneous measurement of 41 key and emerging neurodegeneration-related proteins using as little as 1 µL of plasma, and provides absolute quantification to support translational biomarker discovery.
This panel expands the Olink® Target 48 portfolio, which also includes Olink Target 48 Cytokine, Olink Target 48 Immune Surveillance, and the semi-custom Olink Flex platform, creating an integrated proteomics ecosystem. Together, these solutions enable comprehensive analysis of protein biomarkers relevant to neurodegeneration and inflammation.
Early access user Charlotte Teunissen, Professor of Neurochemistry at the Department of Laboratory Medicine, Amsterdam University Medical Center, said:
“The Target 48 Neurodegeneration panel is a critical tool that enables the detection and quantification of key and emerging neurodegenerative disease biomarkers from plasma and cerebrospinal fluid samples. By generating quantitative data, it ensures reproducible results across and within longitudinal studies, moving a step forward towards clinical utilization.” Yan Zhang, President of the Proteomic Sciences business at Thermo Fisher Scientific, added: “Neurological diseases are complex, multifactorial and urgently in need of translational insights especially with non-invasive proteomic biomarkers for longitudinal monitoring. The panel, designed in close collaboration with leading clinical researchers, offers absolute quantification of multiplex key biomarkers to monitor disease progression and therapeutic responses to power precision medicine.”
Targeted depth: 41 protein biomarkers relevant to Alzheimer’s disease, multiple sclerosis, amyotrophic lateral sclerosis, Parkinson’s disease and other neurodegenerative disorders
Absolute quantification: Parallel measurement of key and emerging biomarkers for neurodegeneration research
Minimal sample input: Requires only 1µL of plasma, enabling high-throughput studies on limited or biobank samples
Scalability and standardization: Compatible with Thermo Fisher’s global network of Olink-equipped labs, supporting reproducibility in multi-center trials
Proven platform: Built on Olink’s gold-standard Proximity Extension Assay (PEA) technology
This launch underscores Thermo Fisher’s commitment to advancing precision medicine and neurology research, complementing its broader suite of tools such as mass spectrometry, cryo-electron microscopy, and multiplex immunoassays. It also builds on initiatives like the UK Biobank proteomics program, the Geisinger Health Study with the Regeneron Genetics Center, and collaborations with leading biopharma companies.
The Olink Target 48 Neurodegeneration panel has been designed to overcome import challenges such as long lead times associated with blood or plasma-derived products. It is fully compatible with the Olink Signature Q100 benchtop system, offering a simplified workflow, minimal maintenance, and streamlined quality control — helping laboratories accelerate biomarker discovery and translational research.